To investigate the efficacy of tamsulosin, a selective alpha-1 blocker, in lower urinary tract symptoms (LUTS) patients with metabolic syndrome (MS).
This prospective, multi-center, clinical trial included men and women (20-75 years old) with LUTS, with or without MS.